MedTrace Logo

Influence of Atorvastatin on Psoriasis Severity and Endothelial Function

NCT01527097 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2015-11-17

No results posted yet for this study

Summary

Patients with psoriasis seem to have increased risk for developing atherosclerosis. This may be due to the fact that psoriasis and atherosclerosis are both caused by inflammation and involvement of cells of the immune system. Atherosclerosis is frequently treated by statins (class of cholesterol lowering drugs), which lower bad cholesterol levels and also reduce inflammation. Some new evidences also suggest that therapy with statins may improve psoriasis skin disease.

The current study aims are to evaluate whether a strong statin named Atorvastatin can improve psoriatic skin disease and functioning of the arteries. The study also aims to evaluate if the activity of these two diseases are related to levels of common inflammatory biomarkers (substance in blood) and whether Atorvastatin can change their levels.

Conditions

Interventions

DRUG

Atorvastatin

Drug: Atorvastatin 80 mg for 6 months following by 40 mg for additional 6 months once daily.

DRUG

Atorvastatin placebo

Atorvastatin 80mg during 6 month and 40mg in additional 6 month period once daily.

Sponsors & Collaborators

  • shmuel fuchs

    lead OTHER

Principal Investigators

  • Shmuel Fuchs, Professor · Rabin Medical Center, Israel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2015-04-30
Completion
2015-04-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01527097 on ClinicalTrials.gov